Amphastar P
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $45.39
- Today's High:
- $48.105
- Open Price:
- $47.47
- 52W Low:
- $26.76
- 52W High:
- $44.46
- Prev. Close:
- $51.37
- Volume:
- 2084318
Company Statistics
- Market Cap.:
- $1.68 billion
- Book Value:
- 10.988
- Revenue TTM:
- $498.99 million
- Operating Margin TTM:
- 21.54%
- Gross Profit TTM:
- $248.86 million
- Profit Margin:
- 18.31%
- Return on Assets TTM:
- 9.51%
- Return on Equity TTM:
- 18.76%
Company Profile
Amphastar P had its IPO on 2014-06-25 under the ticker symbol AMPH.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Amphastar P has a staff strength of 1,615 employees.
Stock update
Shares of Amphastar P opened at $47.47 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $45.39 - $48.11, and closed at $46.64.
This is a -9.21% slip from the previous day's closing price.
A total volume of 2,084,318 shares were traded at the close of the day’s session.
In the last one week, shares of Amphastar P have slipped by -14.47%.
Amphastar P's Key Ratios
Amphastar P has a market cap of $1.68 billion, indicating a price to book ratio of 2.7899 and a price to sales ratio of 2.839.
In the last 12-months Amphastar P’s revenue was $498.99 million with a gross profit of $248.86 million and an EBITDA of $132.73 million. The EBITDA ratio measures Amphastar P's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Amphastar P’s operating margin was 21.54% while its return on assets stood at 9.51% with a return of equity of 18.76%.
In Q4, Amphastar P’s quarterly earnings growth was a positive 63.7% while revenue growth was a positive 11.7%.
Amphastar P’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 20.982
- PEG
- 2.77
Its diluted EPS in the last 12-months stands at $1.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 2.77. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amphastar P’s profitability.
Amphastar P stock is trading at a EV to sales ratio of 2.74 and a EV to EBITDA ratio of 10.1191. Its price to sales ratio in the trailing 12-months stood at 2.839.
Amphastar P stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $741.99 million
- Total Liabilities
- $94.86 million
- Operating Cash Flow
- $-229000.00
- Capital Expenditure
- $22.98 million
- Dividend Payout Ratio
- 0%
Amphastar P ended 2024 with $741.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $741.99 million while shareholder equity stood at $528.66 million.
Amphastar P ended 2024 with $0 in deferred long-term liabilities, $94.86 million in other current liabilities, 6000.00 in common stock, $271.72 million in retained earnings and $3.13 million in goodwill. Its cash balance stood at $156.10 million and cash and short-term investments were $175.76 million. The company’s total short-term debt was $6,049,000 while long-term debt stood at $72.84 million.
Amphastar P’s total current assets stands at $378.32 million while long-term investments were $2.41 million and short-term investments were $19.66 million. Its net receivables were $88.80 million compared to accounts payable of $84.24 million and inventory worth $103.58 million.
In 2024, Amphastar P's operating cash flow was $-229000.00 while its capital expenditure stood at $22.98 million.
Comparatively, Amphastar P paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $46.64
- 52-Week High
- $44.46
- 52-Week Low
- $26.76
- Analyst Target Price
- $41.25
Amphastar P stock is currently trading at $46.64 per share. It touched a 52-week high of $44.46 and a 52-week low of $44.46. Analysts tracking the stock have a 12-month average target price of $41.25.
Its 50-day moving average was $56.73 and 200-day moving average was $41.84 The short ratio stood at 8.95 indicating a short percent outstanding of 0%.
Around 2275.5% of the company’s stock are held by insiders while 6240.8% are held by institutions.
Frequently Asked Questions About Amphastar P
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.